DAIICHI SANKYO, INC. for DAIICHI SANKYO INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding the Affordable Health Care Act (ACA) H.R.1703, Medical Product Communications Act of 2017
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Medicare/Medicaid MMM
Discussions regarding Medicare
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Pharmacy PHA
H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANCE GILGORE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.